Joseph Salama

Overview:

Development of novel radiation treatment techniques for patients with limited metastatic disease, and integration of these treatments with systemic therapies. Treatment of head and neck cancers with chemotherapy, radiation and novel targeted drugs. Improving outcomes for medically inoperable patients with lung cancer with new radiation methods. Developing predictors for toxicity of patients treated with chemotherapy and radiation therapy for non-small cell and small cell lung cancer.

Positions:

Professor of Radiation Oncology

Radiation Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2001

Baylor College of Medicine

Transitional Year Resident, Radiation Oncology

University of Texas Medical School at Houston

Resident, Radiation Oncology

University of Chicago

Chief Resident, Radiation Oncology

University of Chicago

Publications:

NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).

Authors
Chmura, SJ; Winter, KA; Al-Hallaq, HA; Borges, VF; Jaskowiak, NT; Matuszak, M; Milano, MT; Salama, JK; Woodward, WA; White, JR
MLA Citation
Chmura, Steven J., et al. “NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. TPS1117–TPS1117. Crossref, doi:10.1200/jco.2019.37.15_suppl.tps1117.
URI
https://scholars.duke.edu/individual/pub1415778
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
TPS1117
End Page
TPS1117
DOI
10.1200/jco.2019.37.15_suppl.tps1117

Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.

OBJECTIVE. The purpose of this study was to investigate whether, compared with traditional criteria, the modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) improves prediction of local tumor control and survival in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS. Fifty-one HCC lesions (mean size, 3.1 cm) treated with SBRT in 41 patients (mean age, 67 years) were retrospectively included. Each patient underwent CT or MRI before SBRT and at least once after SBRT. Best overall response was categorized using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), iRECIST, World Health Organization (WHO) criteria, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of the Liver (EASL) criteria. Lesions were then classified as local tumor control (i.e., stable disease, partial response, or complete response) or local treatment failure (i.e., progressive disease) by each tumor response criteria. Proportions of local tumor control were compared using the McNemar exact test. The 1-year overall survival was estimated using the Kaplan-Meier method. RESULTS. The median follow-up after SBRT was 21.0 months. The local tumor control rate was 94.1% (48/51) by iRECIST, 88.2% (45/51) by RECIST 1.1, 72.5% (37/51) by WHO criteria, 80.4% (41/51) by mRECIST, and 72.5% (37/51) by EASL criteria. The local tumor control rate was significantly higher according to iRECIST compared with WHO (p = 0.0010) and EASL (p = 0.0225) criteria. The 1-year survival rate for patients with local tumor control according to iRECIST (86.4%) was higher (although not statistically significant) compared with the 1-year survival rate for patients with local tumor control according to the other response criteria. CONCLUSION. iRECIST may provide more robust interpretation of HCC response after SBRT, yielding improved prediction of local tumor control and 1-year survival rates compared with traditional criteria.
Authors
Vernuccio, F; Godfrey, D; Meyer, M; Williamson, HV; Salama, JK; Niedzwiecki, D; Stephens, SJ; Ronald, J; Palta, M; Marin, D
MLA Citation
Vernuccio, Federica, et al. “Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria..” Ajr Am J Roentgenol, vol. 213, no. 6, Dec. 2019, pp. 1232–39. Pubmed, doi:10.2214/AJR.18.20842.
URI
https://scholars.duke.edu/individual/pub1416636
PMID
31613663
Source
pubmed
Published In
Ajr. American Journal of Roentgenology
Volume
213
Published Date
Start Page
1232
End Page
1239
DOI
10.2214/AJR.18.20842

Combining immunotherapy and radiotherapy for the STAR treatment.

Authors
Torok, JA; Salama, JK
MLA Citation
Torok, Jordan A., and Joseph K. Salama. “Combining immunotherapy and radiotherapy for the STAR treatment..” Nat Rev Clin Oncol, vol. 16, no. 11, Nov. 2019, pp. 666–67. Pubmed, doi:10.1038/s41571-019-0277-2.
URI
https://scholars.duke.edu/individual/pub1412038
PMID
31541199
Source
pubmed
Published In
Nature Reviews. Clinical Oncology
Volume
16
Published Date
Start Page
666
End Page
667
DOI
10.1038/s41571-019-0277-2

Radiation Therapy Prior to Immune Checkpoint Inhibition in Metastatic Non-Small Cell Lung Cancer: Determining Toxicity and Efficacy of Combination Treatment

Authors
Price, J; Shantzer, L; Jacobs, CD; Niedzwiecki, D; Clarke, J; Kelsey, CR; Salama, JK; Torok, JA
MLA Citation
Price, J., et al. “Radiation Therapy Prior to Immune Checkpoint Inhibition in Metastatic Non-Small Cell Lung Cancer: Determining Toxicity and Efficacy of Combination Treatment.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. E527–E527. Crossref, doi:10.1016/j.ijrobp.2019.06.2429.
URI
https://scholars.duke.edu/individual/pub1415336
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
105
Published Date
Start Page
E527
End Page
E527
DOI
10.1016/j.ijrobp.2019.06.2429

Authors' Reply.

Authors
MLA Citation
Hong, Julian C., and Joseph K. Salama. “Authors' Reply..” J Natl Compr Canc Netw, vol. 17, no. 8, Aug. 2019, p. xxxixa-xl. Pubmed, doi:10.6004/jnccn.2019.7338.
URI
https://scholars.duke.edu/individual/pub1404166
PMID
31390591
Source
pubmed
Published In
J Natl Compr Canc Netw
Volume
17
Published Date
Start Page
xxxixa
End Page
xl
DOI
10.6004/jnccn.2019.7338